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This journal is ª The Royal Society ofVEGF-loaded graphene oxide as theranostics for
multi-modality imaging-monitored targeting
therapeutic angiogenesis of ischemic muscle†
Zhongchan Sun,‡ab Peng Huang,‡bc Guang Tong,d Jing Lin,bc Albert Jin,e
Pengfei Rong,b Lei Zhu,bf Liming Nie,b Gang Niu,*b Feng Cao*a and Xiaoyuan Chen*b
Herein we report the design and synthesis of multifunctional VEGF-loaded IR800-conjugated graphene
oxide (GO-IR800-VEGF) for multi-modality imaging-monitored therapeutic angiogenesis of ischemic
muscle. The as-prepared GO-IR800-VEGF positively targets VEGF receptors, maintains an elevated level
of VEGF in ischemic tissues for a prolonged time, and finally leads to remarkable therapeutic
angiogenesis of ischemic muscle. Although more efforts are required to further understand the in vivo
behaviors and the long-term toxicology of GO, our work demonstrates the success of using GO for
efficient VEGF delivery in vivo by intravenous administration and suggests the great promise of using
graphene oxide in theranostic applications for treating ischemic disease.1 Introduction
Peripheral vascular disease (PAD) is one of the most common
vascular diseases in the world.1 PAD mainly involves the
impairment of blood ow to the extremities, resulting from
common cardiovascular morbidities such as atherosclerotic
occlusive disease, diabetes mellitus, hyperlipidemia and so on.
In the United States, 8 million people with PAD are devastated
by severe symptoms and complications such as immobility,
intractable ischemia, ulceration, impaired wound healing or
amputation. Only 15–20% of these patients are suitable
candidates for mechanical revascularization therapies such as
surgical bypass or stent implantation. For the rest of the PAD
patients, the only hope of salvaging their affected limbs lies in
therapeutic angiogenesis.2–5The Fourth Military Medical University,
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Chemistry 2013Therapeutic angiogenesis, which aims to stimulate new
blood vessel formation via the sprouting and branching of
existing vessels in ischemic tissues, has received extensive
attention for PAD treatment.4–9 Successful therapeutic angio-
genesis depends on (i) the targeted delivery of various growth
factors such as vascular endothelial growth factor (VEGF) to
ischemic tissues, and (ii) the sustained high concentration of
growth factors in ischemic tissues.10 Clinical trials of adminis-
tering growth factors by either local injection into ischemic sites
or intravenous injection failed to obtain a signicant thera-
peutic effect, most likely due to the short circulation half-life
and lack of specic delivery of growth factors.11–13 Therefore,
targeted delivery and sustained release of growth factors in
ischemic sites is a grand challenge.
Inspired by the targeted drug delivery for tumor therapy
using nanocarriers, some efforts have been made towards the
targeted delivery of VEGF to ischemic sites.4,8,10 Nanocarriers as
novel delivery systems show the following features: (i) nano-
carriers have long circulation in the bloodstream and rapidly
permeate biobarriers such as cell membranes and fenestrated
vasculatures.14,15 (ii) Nanocarriers can easily enter a leaky
angiogenic endothelium, thus providing some specicity,
namely enhanced permeability and retention (EPR) effect.16 (iii)
Nanocarriers display low osmolality.17 (iv) Nanocarriers are
easily decorated with specic biomarkers (peptides,18,19 anti-
bodies,20,21 aptamers,22 and so on) for active targeting.
Graphene, a two-dimensional sp2-hybridized carbon sheet
with exceptional electrical, mechanical, optical, and chemical
properties, has been extensively explored for biomedical appli-
cations,23 such as drug/gene delivery carriers,24–26 enzyme
immobilization,27 and phototherapeutic agents.28–31 Particu-












































View Article Onlinesurface area, which is potentially efficient for protein loading
(e.g. VEGF) via physical adsorption. Although silica nano-
particles have also been used for VEGF delivery,10 graphene
oxide (GO) nanoparticles appear to have the following advan-
tages: (i) high loading efficiency due to two accessible surfaces
of GO;24,25 (ii) high solubility in aqueous solution;25 and (iii)
better biocompatibility.25,28
Herein we report the design and synthesis of multifunctional
VEGF-loaded IR800-conjugated graphene oxide (GO-IR800-
VEGF) for multi-modality imaging-monitored therapeutic
angiogenesis of ischemic muscle. The as-prepared GO-IR800-
VEGF positively targets VEGF receptors of ischemic tissues and
maintains an elevated level of VEGF in ischemic tissues for a
prolonged time, and nally leads to remarkable therapeutic
angiogenesis.2 Results and discussion
The synthetic route for VEGF loaded GO is illustrated in
Fig. S1.† GO was prepared using ake expandable graphite asFig. 1 (a) Schematic structure of VEGF-loaded IR800-conjugated graphene oxide
profile of GO-IR800 (scale bar, 100 nm). (d) UV-vis absorbance and (e) fluorescence em
effects of GO-IR800 (f), free VEGF (g), and GO-IR800-VEGF and (h) on the cultured
6858 | Nanoscale, 2013, 5, 6857–6866the raw material by a modied Hummers method.28,32 Amine
terminated six-arm branched PEG (10 kDa) was conjugated with
GO sheets to improve their aqueous dispersibility, stability, and
biocompatibility. IR800, a commonly used near-infrared (NIR)
uorescent dye, was conjugated with the amino groups of PEG
to allow in vivo tracking of GO biodistribution by NIR uores-
cence imaging. Subsequently, VEGF was loaded onto the two
accessible surfaces of GO via physical adsorption. Fig. 1a shows
the structure of GO-IR800-VEGF. The size and morphology of
as-prepared GO-IR800 were characterized by atomic force
microscopy (AFM). Fig. 1b shows the AFM topography image of
GO-IR800 as very small sheets with a size range of 20–50 nm.
The average thickness of GO-IR800, measured from the height
prole of the AFM image, Fig. 1c, is about 18 nm. The thickness
of a single GO sheet is 1.2 nm. The thickness difference,
16.8 nm, is correlated with the thickness of IR800-conjugated
PEG layers covering both sides of the GO sheet.
Successful conjugation of IR800 and loading of VEGF on GO
sheets were evidenced by UV-vis absorbance spectra. Fig. 1d
shows the UV-vis absorbance spectra of GO, IR800, GO-IR800,(GO-IR800-VEGF). (b) Atomic force microscopy (AFM) image and (c) the height
ission spectra of GO, IR800, GO-IR800, and GO-IR800-VEGF. (f–h) Tube formation
human umbilical vascular endothelial cells (HUVECs) (10 nM VEGF165).












































View Article Onlineand GO-IR800-VEGF. The UV-vis spectrum of GO-IR800 revealed
IR800 peaks superimposing with the absorption curve of GO,
suggesting successful conjugation of IR800 with GO. Compar-
ison of the spectra of GO-IR800 and GO-IR800-VEGF reveals a
new shoulder peak at 280 nm, characteristic of aromatic amino
acids in proteins, seen in GO-IR800-VEGF, but not in GO-IR800,
IR800 or GO, suggesting the presence of VEGF protein mole-
cules on the GO surface. The UV-vis spectrum of the VEGF
protein is shown in Fig. S2.† We used excess GO to guarantee
100% loading of VEGF165 (15 mg VEGF165 and 500 mg of GO). In
this way, we did not detect any free protein (UV absorbance at
280 nm) in the removed solution aer centrifugation–ltration
through 100 kDa MWCO Amicon lters. Fig. 1e represents the
uorescence spectra of GO, IR800, GO-IR800, and GO-IR800-
VEGF. The uorescence emission spectra of IR800, GO-IR800,
and GO-IR800-VEGF are similar to the maximum emission at
800 nm. The samples were normalized to the same IR800
concentration (OD value) measured by UV-vis. The results also
showed slight uorescence quenching of IR800 in the GO-
IR800, which is likely owing to the direct contact between IR800
and aromatic regions of the GO sheets.
Aer synthesis of GO-IR800-VEGF, the cellular toxicity of GO-
IR800-VEGF was evaluated on MDA-MB-435 cells using MTT
assay. Cell viability was normalized by the control group of cells
without GO-IR800-VEGF. As shown in Fig. S3,† the results sug-
gested a negligible cytotoxicity of GO-IR800-VEGF on MDA-MB-
435 cells within the concentration range of 0–200 mg mL1.
Then we tested whether VEGF preserved its pro-angiogenetic
effect aer loading onto GO-IR800 nanocarriers. Endothelial
cells play essential roles in the angiogenic process within theFig. 2 Characterization of a mouse hindlimb ischemia model. (a) Three dimension
Laser Doppler images of control and ischemia groups. (c) Quantitative analysis of tissu
compared with the control group). (d) Photoacoustic (PA) images of the oxygen sat
(%) in ischemic limbs and control non-ischemic limbs (**, P < 0.01, as compared wi
This journal is ª The Royal Society of Chemistry 2013skeletal muscle post-ischemia.33 To directly investigate the
effect of GO-IR800-VEGF on endothelial cells in vitro, we
determined the effect of GO-IR800-VEGF on tube formation of
human umbilical vascular endothelial cells (HUVECs).
Compared with the pure GO-IR800 (Fig. 1f), GO-IR800-VEGF
was able to signicantly enhance tube formation to an extent
similar to free VEGF treatment (10 nM VEGF165, Fig. 1g and h).
Both VEGF and GO-IR800-VEGF treated HUVEC cells developed
complex mesh-like structures while GO-IR800 treated cells only
form close polygons. VEGF and GO-IR800-VEGF treated cells
also showed a signicantly longer total capillary tube length
than that of GO-IR800 (p < 0.01, Fig. S4†). This result indicated
that the pro-angiogenic effect of VEGF on endothelial cells
in vitro can be well preserved aer loading onto GO-IR800
nanocarriers.
To assess the theranostic potential of GO-IR800-VEGF in vivo,
we investigated its therapeutic angiogenesis effect in ischemic
muscle using a well-established model of mouse hindlimb
ischemia. This model is widely used for mimicking PAD and is
established by ligation and excision of a section of femoral artery
and all branches originated from this section of femoral artery in
the right hindlimb. The sham operated le hindlimb serves as a
control.34 Low blood ow to the right hindlimb distal to the
ligation site was conrmed by multiple imaging modalities
(Fig. 2), including power Doppler imaging, color Doppler
imaging, laser Doppler imaging (LDI), and photoacoustic
(PA) imaging. Before surgery, power Doppler and color Doppler
imaging in three dimensional modes displayed clear and
unimpeded blood ow within femoral artery and vein and
multiple branches derived from these stem vessels (Fig. 2a).al power Doppler and color Doppler images of control and ischemia groups. (b)
e blood perfusion in ischemic limbs and control non-ischemic limbs (**, P < 0.01, as
uration (sO2) map of control and ischemia groups. (e) Quantitative analysis of sO2
th the control group).
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Fig. 3 Real-time in vivo and ex vivo fluorescence imaging. (a) Real-time in vivo NIR fluorescence images after intravenous injection of GO-IR800-VEGF in mice at
different time points; (b and c) ex vivo NIR fluorescence images of mice tissues (from left to right: heart, liver, spleen, lung, kidneys), harvested at a 24 h time point from
post-injection mice. (d) Representative fluorescent image of ischemic (left limb) and nonischemic (right limb) tissues from the mouse injected with GO-IR800. (e)












































View Article OnlineColor Doppler imaging further distinguishes blood ow with
different directions in different colors. Red and blue colors
indicate the blood within vessel ows toward and away from theFig. 4 Histological examination of the level of VEGFRs and VEGF in ischemic hindl
non-ischemic (right) limbs. VEGFR1 protein is in green and nuclei were stained wi
VEGFR2 protein of cryosectioned ischemic (left) and non-ischemic (right) limbs. VEGF
of VEGF protein of an ischemic limb in GO-IR800 (left), free VEGF (middle) and GO-IR
in blue. (d) Fluorescence images of the ischemic limb in GO-IR800 (left), free VEGF (m
red (arrows) and nuclei are in blue. Muscle fibers appear green due to autofluoresc
6860 | Nanoscale, 2013, 5, 6857–6866transducer, respectively. Aer ischemic injury, abrupt disrup-
tion of right femoral artery blood ow could be observed in both
powerDoppler and color Dopplermodeswith only a few traces ofimbs. (a) Immunostaining of VEGFR1 protein of cryosectioned ischemic (left) and
th 40 ,6-diamidino-2-phenylindole (DAPI) and are in blue. (b) Immunostaining of
R1 protein is in red and nuclei are in blue (scale bar ¼ 50 mm). (c) Immunostaining
800-VEGF (right) treated groups, respectively. VEGF protein is in red and nuclei are
iddle) and GO-IR800-VEGF (right) treated groups. GO-IR800 nanoparticles are in
ence (scale bar ¼ 25 mm).












































View Article Onlineblood ow le within the muscle (Fig. 2a). Low blood perfusion
in the hindlimb tissue, resulted from the ligation and excision of
the right femoral artery, could also be observed using LDI
(Fig. 2b), which showed that the regional blood owwas reduced
to only 20% of normal levels aer ischemic surgery (1.004 
0.201 vs. 0.201  0.070; P < 0.01). Observation of reduction in
blood ow was seconded by reduction in both total and
oxygenated haemoglobin content in ischemic muscle demon-
stratedby PAmode imaging (Fig. 2d). Oxygen saturation (sO2) is a
measure of the amount of hemoglobin binding sites occupied by
oxygen and is expressed a percentage value of total binding sites
(both deoxyhemoglobin and oxyhemoglobin). A low haemoglo-
bin level resulted in low oxygen saturation (43.82  6.51% vs.
21.28  3.82%; P < 0.01). All these results indicate successful
construction of this standard animal model of PAD.
Aer successful establishment of the mouse hindlimb
ischemia model, we rst tested whether GO-IR800-VEGF could
target the ischemic hindlimb. A single dose of VEGF alone
(3 mg), GO-IR800 (200 mL, 0.5 mg mL1), or GO-IR800-VEGF
(200 mL, 0.5 mg mL1 GO-IR800, 3 mg VEGF) was injected
intravenously via tail vein on day 3 post-induction of the hin-
dlimb ischemia. NIR uorescence imaging of right ischemic
and le normal hindlimbs was subsequently performed at
multiple designated time points to evaluate the dynamicFig. 5 Therapeutic angiogenesis of ischemic muscle. (a) Laser Doppler images of GO
days 1, 7 and 14 post-surgery. (b) Quantitative analysis of tissue blood perfusion in is
P < 0.05, as compared with the VEGF treated group on day 14). (c) Photoacoustic (PA
(middle) and GO-IR800-VEGF (right) treated groups on day 14 post-surgery, respectiv
of the above three groups (**, P < 0.01, as compared with the GO-IR800 group; #, P <
tomography (PET) images at 1 h after intravenous injection of 18F-AlF-NOTA-PRGD2 (
ischemic tissue three groups above (**, P < 0.01, as compared with the GO-IR800 g
This journal is ª The Royal Society of Chemistry 2013accumulation of GO-IR800-VEGF in an ischemic hindlimb in
vivo (Fig. 3). The uorescence intensity of ischemic limbs is
stronger than that of non-ischemic limbs at all of the time
points examined (Fig. 3a), suggesting that VEGF-loaded GO-
IR800 nanocarriers could substantially target ischemic muscle.
These observations could be ascribed to the increased perme-
ability of blood vessels in hypoxic tissues, which has been
conrmed by previous studies.4,10 Ischemia in peripheral tissue
leads to upregulated expression of a variety of angiogenic
factors that may enhance the localized blood vessel perme-
ability as they activate and mobilize endothelial cells in blood
vessels.
To conrm the results observed in vivo, ex vivo evaluation of
VEGF-loaded GO-IR800 accumulation in ischemic muscle was
also performed. At 24 h time point post-injection, the mice were
sacriced and organs of GO-IR800 and GO-IR800-VEGF injected
mice were harvested for ex vivo imaging (Fig. 3b and c). The
uorescence signal displayed in the liver could be attributed to
the high uptake of GO-IR800 or GO-IR800-VEGF by the reticu-
loendothelial system (RES). The strong uorescence signal in
the kidneys and bladder suggests renal clearance of GO-IR800
or GO-IR800-VEGF aer circulation in the bloodstream.
Compared to non-ischemic hindlimbs, ischemic hindlimbs
demonstrated much higher uorescence levels, with or without-IR800 (top), free VEGF (middle) and GO-IR800-VEGF (bottom) treated groups on
chemic limbs and control non-ischemic limbs (*, P < 0.05, as compared to day 1; #,
) images for tissue oxygen saturation (sO2) detection of GO-IR800 (left), free VEGF
ely. (d) Quantitative analysis of tissue oxygen saturation (%) within ischemic limbs
0.05, as comparedwith the free VEGF group). (e) Representative positron emission
18F-Alfatide) in the above three groups. (f) Quantitative analysis of tracer uptake in
roup; #, P < 0.05, as compared with the free VEGF group).












































View Article Onlineloaded VEGF, which is consistent with the aforementioned
in vivo data. Major organs of GO-IR800-VEGF treated mice were
collected for histology analysis. No noticeable sign of organ
damage was observed from hematoxylin and eosin (H&E)
stained organ slices (see Fig. S5†), suggesting the promise of
using GO-IR800-VEGF for in vivo applications.
Importantly, both GO-IR800 and GO-IR800-VEGF were
broadly distributed throughout the entire ischemic tissue below
the ligation site (Fig. 3d and e), rather than being locally
centralized only surrounding the site at which femoral artery
was blocked. The observed even and extensive distribution of
nanocarriers in a large area of ischemic tissue suggests that
therapeutic molecules delivered by GO are able to reach a large
volume of targeted tissue. Interestingly, the relative uores-
cence ratio of ischemic limbs to non-ischemic limbs in the GO-
IR800-VEGF treated group was found to be much higher than
that of the GO-IR800 treated group (3.39 vs. 1.84) (see Fig. S6†),
suggesting that VEGF itself might also play a role in the accu-
mulation of GO-IR800-VEGF in ischemic tissue, mostly likely
due to the up-regulation of VEGF receptors in the ischemic
tissue induced by hypoxia. Thus, VEGFmight function as both a
guiding agent and a therapeutic drug. This hypothesis was also
supported by ex vivo histological evaluation for VEGF receptor
(VEGFR) expression and local VEGF level. Immunostaining
demonstrated up-regulated expression of both VEGFR1 andFig. 6 Histological confirmation of therapeutic angiogenesis. (a) Immunostaining
VEGF treated groups on day 9 post-surgery, respectively. (b) Immunostaining of a-SM
surgery. CD31 protein is in red, a-actin protein is in green and nuclei are in blue (sc
6862 | Nanoscale, 2013, 5, 6857–6866VEGFR2 in an ischemic region compared with a non-ischemic
region (Fig. 4a and b). Meanwhile, an enhanced level of VEGF in
the ischemic muscle derived from GO-IR800-VEGF treated mice
could also be detected by immunostaining (Fig. 4c). Further-
more, uorescence images of cryosectioned ischemic limbs also
indicate a signicant increase in deposition of nanocarriers in
ischemic muscle bers aer GO-IR800-VEGF injection, as
compared to both non-ischemic tissue and ischemic tissue
derived from GO-IR800 treated mice (Fig. 4d).
To assess the angiogenic response to intravenous injection
of GO-IR800-VEGF, multiple imaging modalities were used to
evaluate the therapeutic effect. Firstly, LDI at various time
points was performed to monitor the blood perfusion in hin-
dlimbs. On day 1 post-induction of ischemia, the regional blood
ow in ischemic limbs was abruptly decreased to approximately
20% of normal limbs in all groups aer ischemic surgery as
expected (Fig. 5a). The untreated group showed a slow increase
in blood ow from 20% to 40% of normal values over time,
mainly due to the spontaneous recovery induced by endogenous
capillary formation and the sprouting of collateral arteries,35 a
similar extent of blood ow recovery was observed in the
GO-IR800 treated group. Administration of free VEGF,
mimicking the routine delivery approach, resulted in no
signicant difference from the GO-IR800 treatment control
group. Nonetheless, GO-IR800-VEGF led to much betterof CD31 protein of the cryosectioned ischemic limb in free VEGF and GO-IR800-
A protein of a cryosectioned ischemic limb in two groups above on day 14 post-
ale bar ¼ 25 mm).












































View Article Onlinerecovery of blood perfusion over entire 14 days and reached
nearly 60% of the non-ischemic tissue (Fig. 5b), a 1.5-fold
increase as compared to the other conditions at the end point of
this study.
In addition, PA mode imaging was used to detect the
regional oxygen saturation in ischemic tissue. Oxygen satura-
tion serves as an important index to monitor functional
angiogenesis. GO-IR800-VEGF treatment was capable of signif-
icantly increasing oxygen supply to ischemic muscle, as evi-
denced by the much stronger signal intensity observed in the
GO-IR800-VEGF treated group 2 weeks post-surgery, as
compared to the other groups (Fig. 5c and d). The elevated
oxygen delivery is most likely attributed to the enhanced
capillary formation and small artery sprouting within ischemic
tissue by GO-IR800-VEGF treatment. This result of increased
oxygen saturation suggests that increased angiogenesis by
GO-IR800-VEGF treatment can be translated into elevation of
oxygen supply to ischemic tissue, which, in turn, enhances the
survival and function of the ischemic hindlimb.
Integrins, a family of proteins, have been well documented
on their impact in cellular adhesion and migration into the
extracellular matrix (ECM).36 Among this family, avb3 integrin is
highly expressed on activated neovascular endothelial cells and
plays an essential role in endothelial cell survival and migration
during angiogenesis.37 Therefore, integrin avb3 is able to func-
tion as a target for angiogenesis imaging with the specic
probes.38–40 In terms of good imaging qualities and convenient
synthesis, 18F-AlF-NOTA-PRGD2 (18F-Alfatide) has been repor-
ted to be a promising tracer for PET imaging of integrin avb3
expression.41–43
In the present study, static PET imaging was also performed
1 week post-treatment to evaluate angiogenesis using 18F-Alfa-
tide as the imaging probe. Fig. 5e shows representative coronal
PET images of mouse hindlimbs at 1 h post injection of 18F-
Alfatide (100 mCi per mouse). Based on PET quantication
(Fig. 5f), the ischemic tissue uptake of 18F-Alfatide aer GO-
IR800-VEGF treatment (0.77  0.06%ID per g) is signicantly
higher than that in the GO-IR800 group (0.56  0.05%ID per g;
P < 0.01) and the VEGF treatment group (0.67  0.05%ID per g;
P < 0.05), suggesting the strong therapeutic angiogenesis effect
of GO-IR800-VEGF.
The pro-angiogenetic effect of GO-IR800-VEGF treatment
was conrmed by quantication of blood vessel densities using
immunostaining of CD31 (marker for endothelial cell) and a-
SMA (marker for small arteriole). As shown in Fig. 6, GO-IR800-
VEGF treatment dramatically increased CD31 (Fig. 6a) and a-
SMA (Fig. 6b) expression levels over VEGF treatment. The
upregulation of both CD31 and a-SMA suggests the increased
density of both capillaries and small arterioles.3 Experimental section
Synthesis of PEG-modied graphene oxide
Graphene oxide (GO) was prepared using ake expandable
graphite as the raw material by a modied Hummers method.
To prepare PEG-modied GO, 5 mL of GO aqueous suspension
(3 mg mL1) was sonicated for 30 min. Then NaOH (0.12 gThis journal is ª The Royal Society of Chemistry 2013mL1) was added to the GO suspension under sonication for
another 3 h. The resulting solution was neutralized, puried,
and separated by repeated rinsing and ltration, then a solution
of 6-arm-polyethylene glycol-amine (Sunbio Inc.) (3 mg mL1)
was added to the GO solution (0.5 mg mL1) and the mixture
was sonicated for 5 min. N-(3-Dimethylaminopropyl-N0-ethyl-
carbodiimide) hydrochloride (EDC, from Fluka Inc.) was then
added to the mixture in two equal portions to give a nal
concentration of 1 mg mL1. The reaction was allowed to stand
overnight, yielding a PEG-modied GO solution which was
stored at 4 C for further use.
Synthesis of VEGF-loaded IR800-conjugated graphene oxide
(GO-IR800-VEGF)
The excess PEG in the as-synthesized PEG-modied GO sample
was removed by Amicon centrifugal lters (Millipore) with 100
kDa molecular weight cut off (MWCO) and washed with water
several times. The puried PEG-modied GO (0.5 mgmL1) was
reacted with an amine reactive dye, IR800 (LI-COR Biosciences)
at 0.1 mg mL1 in a pH 7.5 phosphate buffer (0.02 M). The
reaction was allowed to stand overnight at room temperature in
the dark. The excess dye was removed by centrifugation ltra-
tion through 100 kDa MWCO Amicon lters and washed with
water 8 until no IR800 could be detected in the supernatant by
UV-vis spectroscopy.
Recombinant mouse vascular endothelial growth factor-165
(VEGF-A or VEGF-165) is a nonglycosylated, disulde-linked
homodimer, containing 165 amino acids with a molecular mass
of 39 kDa. VEGF-165 was purchased from Shenandoah
Biotechnology, Inc. 1 mL of 0.5 mg mL1 GO-IR800 in PBS
buffer (pH ¼ 7.4) was mixed with 15 mg VEGF-165 and shaken
overnight at 4 C. Excess VEGF-165 were removed by centrifu-
gation ltration through 100 kDa MWCO Amicon lters and
washed away with PBS buffer (pH ¼ 7.4) several times. GO-
IR800-VEGF retained in the lter was washed 4 to 6 times and
re-suspended in PBS buffer (pH ¼ 7.4). The formed GO-IR800-
VEGF was stored at 4 C.
Characterization
Briey, AFM imaging of the samples was carried out under a
range of deposition conditions in uid, rinsed with deionized
water and dried under a gentle ow of N2 or Ar gas, using gentle
tapping-mode and mostly with a PicoForce Multimode AFM
(Bruker, CA) consisting of a Nanoscope V controller, a type E
scanner head, and a sharpened TESP-SS (Bruker, CA), or a
similar AFM cantilever. For GO-IR800 sample visualization,
suitable surface attachment of the respective sample was ach-
ieved readily by 5 min incubation of 5 mL of 6 mg mL1 uid
suspension on freshly peeled and slightly tilted mica on metal
disks of 12 mm diameters. The excess uid was blown away by
an inert gas gush, followed by a complete drying of the sample
surface under gentler gas ow. The sample was then sealed into
the instrument compartment dehumidied by Drierite parti-
cles and imaged via standard optimizations and a range of
imaging settings to enhance reliability. For fuller comparison,












































View Article Online30–50 mL of deionized water to remove salt deposits, dried
under gentle air ow, and re-imaged similarly. AFM images
were evaluated within the Nanoscope soware (version 7.3,
Bruker, CA), and exported to Image J (version 1.4x, NIH,
Bethesda, MD) for further analyses and display.
UV-vis spectra were recorded at 20 C using a Genesys 10S
UV-vis spectrophotometer (Thermo Scientic, Waltham, MA)
equipped with a 10 mm quartz cell, where the light path length
was 1 cm. Fluorescence spectra were recorded on a Hitachi F-
7000 spectrouorimeter (HITACHIH, Japan).
Tube formation assay
100 mL of Matrigel (growth factor reduced, BD Biosciences) was
added to each well of a 48-well plate, and polymerized at 37 C
for 1 hour. HUVECs (1  104) were seeded onto Matrigel, in
endothelial cell basal medium-2 with EGM-2 Bullet Kit. Aer 1
hour culture, GO-IR800-VEGF, GO-IR800 or VEGF (10 nM) was
added.
Animals
All experiments were performed in adherence with the National
Institutes of Health guidelines on the use of laboratory animals
and were approved by the National Institutes of Health
Committee on Animal Care.
Mice hindlimb model
Hindlimb ischemia was achieved by right femoral artery exci-
sion as previously described.44 In brief, ischemia was induced by
ligation and segmental resection of the femoral vessels prox-
imal to the bifurcation with silk sutures (#7.0). A sham opera-
tion was performed in the le hindlimb without ligation and
excision of the femoral artery, such that the right hindlimb is
ischemic and the contralateral le hindlimb serves as a control.
Hindlimb muscles such as tibialis anterior (TA), extensor dig-
itorum longus, gastrocnemius, soleus, and plantaris were har-
vested at various time points aer the induction of ischemia
and processed for histological examination. All the measure-
ments were performed in contralateral and ischemic muscles of
the hind limbs.
Real-time acquisition of NIR uorescence images in vivo
Optical data acquisition and analysis were done using DyCE
function in Maestro 2.0 in vivo imaging system (Cambridge
Research & Instrumentation, Woburn, MA). 0.3 mg VEGF or the
same concentration of VEGF loaded with GO-IR800 or an equal
amount of GO-IR800 alone in 100 ml PBS were each injected via
tail vein into Balb/c mice (n ¼ 5) on day 2 post-hindlimb
ischemia surgery. Aer 0.5, 1, 2, 4, 6 and 24 h post-injection, the
mice were subjected to in vivo real-time optical imaging by
Maestro 2.0 congured for NIR detection. During the injection
and image acquisition process, the mice were anesthetized with
1.0–2.0% isourane in oxygen delivered at a ow rate of 1.0 L
min1. Aer completion of the image acquisition, spectral un-
mixing yielded the pseudocolored images of the pure spectrum
of ZW-1. Image pre-processing and analysis were performed6864 | Nanoscale, 2013, 5, 6857–6866using the DyCE soware provided by the manufacturer. For
quantitative comparison, regions of interest (ROIs) were drawn
over ischemic and non-ischemic hindlimbs, and the average
signal (106 photons per cm2 per s) for each area wasmeasured.
Results were presented as mean  S.D.
Small animal PET imaging
In the 1st week aer hindlimb ischemia surgery, PET imaging
scans were performed using an Inveon microPET scanner
(Siemens Preclinical Solutions). Balb/c mice of different groups
were anesthetized with 1.0–2.0% isourane in oxygen delivered
at a ow rate of 1.0 L min1 and approximately 3.75 MBq
(100 mCi) of 18F-AlF-NOTA-PRGD2 (18F-Alfatide) was adminis-
tered via tail vein injection. Ten minutes static PET images were
acquired at 1 h aer injection of the tracer.
The images were reconstructed by a three-dimensional
ordered subsets expectation maximization (3D-OSEM) algo-
rithm, and no correction was applied for attenuation or
scatter. Image analysis was done using ASI Pro VMTM soware.
The total RGD uptake (%ID per g) of the ischemic hindlimb
tissue was determined by drawing three-dimensional regions of
interest (ROIs) surrounding an entire limb on the coronal
images. The radioactivity contained in the ROI divided by the
dose administered to the animal gave the%ID per g. Each group
contained 4–5 mice.
Power Doppler and color Doppler scans of hindlimbs
Before and 1 day post-hindlimb ischemia surgery, power
Doppler and color Doppler scans were performed using a Vevo
2100 Imaging System (VisualSonics Vevo 2100, Toronto, ON,
Canada). Aer Balb/c mice were anesthetized with 1.0–2.0%
isourane in oxygen delivered at a ow rate of 1.0 L min1, ow
velocity and spatial vascular prole in the right hindlimb were
evaluated by power Doppler with a 32 MHz linear transducer in
three-dimensional mode. Percent vascularity, an index of rela-
tive vascular density, was calculated by measurement tools in
the power Doppler mode to assess the vascularity of the hin-
dlimb. Color Doppler mode in three-dimension was also used to
provide a visual overview of ow within the normal and
ischemic skeletal muscle tissue as well as delineate the ow
direction and velocity by red and blue color spectrums. Small
vessels, which cannot be detected in B-mode, are able to be
rapidly identied by color Doppler mode.
Oxygen supply assessments by photoacoustic (PA) mode scan
Before, 1 day, and 14 days post-surgery, (PA) mode scans were
performed based on a Vevo LAZR platform (VisualSonics Vevo
LAZR, Toronto, ON, Canada). Aer Balb/c mice were anes-
thetized with 1.0–2.0% isourane in oxygen delivered at a
constant ow rate of 1.0 L min1, oxygenated hemoglobin and
total hemoglobin within the vessel of the hindlimb were
detected by PA mode scan with 700/750 nm wavelength and
these functional hemodynamic results can be visually overlaid
with anatomical images. Hemoglobin content and quantica-
tion and oxygen saturation calculation and quantication












































View Article Onlinerespectively. Oxygen saturation (sO2%) was calculated as the
percent of oxygenated hemoglobin in total hemoglobin in the
same regions of interest (ROI) to indicate the oxygen supply to
the hindlimb at different time points.Immunouorescence staining
Mouse skeletal muscles within the ischemic hindlimb 14 days
aer surgery were harvested for immunouorescence staining.
Aer the sample was embedded in O.C.T. and snap-frozen on
dry ice, serial cryosections (10 mm thickness) were cut and
mounted on glass slides (Fisher, Pittsburgh, PA, USA). Aer
drying at room temperature, slides were xed with 4% para-
formaldehyde in PBS for 10 min and later incubated with 1%
bovine serum albumin (BSA; Sigma) in PBS.
For single antibody staining, slides were incubated with
rabbit anti-VEGFR2 (diluted 1 : 150; Abcam, Cambridge, MA,
USA),mouse anti-VEGF (diluted 1 : 150; Abcam,Cambridge,MA,
USA) ormouse anti-VEGFR1 (diluted 1 : 200; Abcam,Cambridge,
MA, USA). The combinations were visualized using a Cy3-
conjugated anti-rabbit (Sigma) or uorescein isothiocyanate
(FITC)-conjugated anti-mouse (Sigma) secondary antibodies.
For double antibodies staining, slides were incubated with
rabbit anti-CD31 (diluted 1:200; Abcam, Cambridge, MA, USA)
or rabbit anti-alpha-smooth muscle actin (a-SMA) (diluted
1:150; Abcam, Cambridge, MA, USA) mixed with mouse anti-a-
actin (skeletal) primary antibodies solution (diluted 1:250;
Abcam, Cambridge, MA, USA), respectively. The combinations
were visualized using a mixture of Cy3-conjugated anti-rabbit
(Sigma) and uorescein isothiocyanate (FITC)-conjugated anti-
mouse (Sigma) secondary antibodies.Statistical analysis
Results were presented as mean  S.D. Two-tailed paired and
unpaired Student's t-tests were used to determine differences
within groups and between groups, respectively. P value <0.05
was considered statistically signicant.4 Conclusions
In summary, VEGF-loaded IR800-conjugated graphene oxide
(GO-IR800-VEGF) specically and efficiently targets ischemic
muscle tissues in the murine hindlimb ischemia model. Both
active and passive targeting of GO-IR800-VEGF led to a high
local VEGF concentration in the ischemic tissue. The in vivo
pharmacokinetics and biodistribution of GO-IR800-VEGF was
successfully monitored by NIR uorescence imaging. The
therapeutic angiogenesis of ischemic muscle was conrmed by
multiple imaging modalities including LDI, PA, and PET
imaging, which were further validated by ex vivo immunos-
taining of CD31 and a-SMA. Although more efforts are
required to further understand the in vivo behaviors and the
long-term toxicology of GO, our work demonstrates the success
of using GO for efficient VEGF delivery in vivo by intravenous
administration and suggests the great promise of using gra-
phene oxide in theranostic applications for treating ischemic
disease.This journal is ª The Royal Society of Chemistry 2013Acknowledgements
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